Hologic's (HOLX) New Launches Aid, Macroeconomic Issues Ail
NASDAQ · 2d ago
Reuters · 3d ago
Hologic: A Strong Buy Amidst Growth, Innovation, and Favorable Market Dynamics
TipRanks · 4d ago
Analysts Conflicted on These Healthcare Names: Tilray (TLRY), Hologic (HOLX) and Bicycle Therapeutics (BCYC)
TipRanks · 4d ago
Hologic Price Target Maintained With a $90.00/Share by Needham
Dow Jones · 4d ago
Needham Reiterates Buy on Hologic, Maintains $90 Price Target
Benzinga · 4d ago
RBC Capital Sticks to Its Hold Rating for Hologic (HOLX)
McNamara covers the Healthcare sector, focusing on stocks such as QuidelOrtho and Bio-Rad Laboratories. The company’s shares closed yesterday at $77.38. The analyst consensus on Hologic is a Moderate Buy with an average price target of $85.33.
TipRanks · 6d ago
Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It
NASDAQ · 6d ago
Weekly Report: what happened at HOLX last week (0401-0405)?
Weekly Report · 6d ago
U.S. RESEARCH ROUNDUP-Conocophillips, Fastly, Vital Energy
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Broadcom, Fastly, Vital Energy, Conocophillips, 3M among companies with revised targets. Broad com resumes coverage with buy rating; Deutsche Bank resumes coverage.
Reuters · 6d ago
Reuters · 04/08 06:27
Calculating The Intrinsic Value Of Hologic, Inc. (NASDAQ:HOLX)
Using the 2 Stage Free Cash Flow to Equity, Hologic fair value estimate is US$93.88 Current share price of US$77.28 suggests Hologic is potentially trading close to its fair value. Hologic's fair value is 12% higher than its analyst price target. We use the Discounted Cash Flow model to estimate the attractiveness of Hologic, Inc. (NASDAQ:HOLX)
Simply Wall St · 04/05 12:28
Hologic Is Maintained at In-Line by Evercore ISI Group
Dow Jones · 04/04 16:54
Hologic Price Target Raised to $78.00/Share From $76.00 by Evercore ISI Group
Dow Jones · 04/04 16:54
Evercore ISI Group Maintains In-Line on Hologic, Raises Price Target to $78
Benzinga · 04/04 16:44
The Analyst Landscape: 4 Takes On Hologic
Four analysts have released ratings for Hologic (NASDAQ:HOLX) in the last three months. Hologic manufactures proprietary products for the healthcare needs of women. The company has an average 12-month price target of $88.0. The firm's revenue growth over the past three months has been slower than the industry average.
Benzinga · 04/03 15:00
CORRECTION: Citigroup Upgrades Hologic to Buy, Raises Price Target to $95 - Rating change updated
Benzinga · 04/03 14:49
Hologic Price Target Raised to $95.00/Share From $80.00 by Citigroup
Dow Jones · 04/03 14:39
Hologic Raised to Buy From Neutral by Citigroup
Dow Jones · 04/03 14:39
Citigroup Maintains Neutral on Hologic, Raises Price Target to $95
Benzinga · 04/03 14:28
Webull provides a variety of real-time HOLX stock news. You can receive the latest news about Hologic Inc through multiple platforms. This information may help you make smarter investment decisions.
About HOLX
Hologic, Inc. is a medical technology company primarily focused on improving women's health and well-being through early detection and treatment. The Company is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products. It operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The Diagnostics segment offers a wide range of diagnostic products, which are used primarily to aid in the screening and diagnosis of human diseases. The Breast Health segment offers a broad portfolio of solutions for breast cancer care primarily in the areas of radiology, breast surgery, pathology and treatment. The GYN Surgical segment products include MyoSure hysteroscopic tissue removal system, NovaSure endometrial ablation system, Fluent fluid management system and Acessa ProVu laparoscopic radiofrequency ablation system. The Skeletal Health segment products include Horizon DXA Systems and Fluoroscan Insight FD.